Literature DB >> 18941400

Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.

Ruta Gupta1, Bonnie Balzer, Maria Picken, Adeboye O Osunkoya, Tanuja Shet, Randa Alsabeh, Daniel Luthringer, Gladell P Paner, Mahul B Amin.   

Abstract

Pax 2, expressed by metanephric mesenchyme is vital for renal tubule formation and development. Carbonic anhydrase IX (CA IX) is implicated in cell proliferation, adhesion, and invasion. Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants. Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX. Clear cell RCC (28/30, 93%), oncocytoma (17/17, 100%), papillary RCC (16/30, 53%), and mucinous tubular spindle cell carcinoma (3/4, 75%) demonstrated nuclear immunoreactivity with Pax 2, whereas the other subtypes were nonreactive. Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal tumors with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive. This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative). CA IX expression has potential diagnostic implications including (i) clear cell RCC (positive) versus chromophobe RCC (negative) and (ii) urothelial carcinoma (positive) versus collecting duct carcinoma (negative). These antibodies may reliably discriminate between clinically significant subtypes of RCC with overlapping cytoarchitectural features.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18941400     DOI: 10.1097/PAS.0b013e318181b828

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib.

Authors:  Fade Mahmoud; Al-Ola Abdallah; Konstantinos Arnaoutakis; Issam Makhoul
Journal:  Perm J       Date:  2016-06-27

2.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

Review 3.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

4.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

5.  Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.

Authors:  Elizabeth M Genega; Musie Ghebremichael; Robert Najarian; Yineng Fu; Yihong Wang; Pedram Argani; Chiara Grisanzio; Sabina Signoretti
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

Review 6.  Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.

Authors:  Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

7.  Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.

Authors:  Jérôme Verine; Jacqueline Lehmann-Che; Hany Soliman; Jean-Paul Feugeas; Jean-Sébastien Vidal; Pierre Mongiat-Artus; Stéphanie Belhadj; Josette Philippe; Matthieu Lesage; Evelyne Wittmer; Stéphane Chanel; Anne Couvelard; Sophie Ferlicot; Nathalie Rioux-Leclercq; Jean-Michel Vignaud; Anne Janin; Stéphane Germain
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

8.  IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors.

Authors:  Hailong Ruan; Zhengshuai Song; Qi Cao; Dong Ni; Tianbo Xu; Keshan Wang; Lin Bao; Junwei Tong; Haibing Xiao; Wen Xiao; Gong Cheng; Zhiyong Xiong; Huageng Liang; Di Liu; Liang Wang; Tredan Olivier; Boyle Helen Jane; Hongmei Yang; Xiaoping Zhang; Ke Chen
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

9.  Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.

Authors:  Lisha Wang; Sean R Williamson; Mingsheng Wang; Darrell D Davidson; Shaobo Zhang; Lee Ann Baldridge; Xiang Du; Liang Cheng
Journal:  Mol Cancer       Date:  2014-02-26       Impact factor: 27.401

10.  Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.

Authors:  Patrícia Patrício; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Mafalda Almeida; João Diogo Barros-Silva; Joana Vieira; Paula Cristina Dias; Francisco Lobo; Jorge Oliveira; Manuel R Teixeira; Rui Henrique; Carmen Jeronimo
Journal:  J Cell Mol Med       Date:  2013-07-26       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.